StockData
Mangoceuticals, Inc. logo

Mangoceuticals, Inc. (MGRX) stock

MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 7/30
$0.15−0.03 (-16.22%)

Close on Nov 13, 2026Market cap $3.34MP/E –Yield –

Earnings

Mangoceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Mangoceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2024ended Jun 30, 2024Aug 15, 2024before the open–––Release
Q3 FY2023ended Sep 30, 2023Oct 19, 2023before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Mangoceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Mangoceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Mangoceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
    Update
  2. Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
    News
  3. Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
    Update
  4. Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures,
    Update
  5. Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against
    Update
  6. Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
    Update
  7. Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
    News
  8. Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
    News
  9. Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management
    News
  10. Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum
    Update
  11. Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven
    Update
  12. Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using
    News
  13. Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based
    News
  14. Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
    News
  15. Announces Formation of Strategy and Alternatives Committee
    News

See a number that looks wrong?